The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study

Basit Öğe Kaydı
dc.authoridDilber, Beril/0000-0002-7633-0060
dc.authorscopusid35310592400
dc.authorscopusid54413097400
dc.authorscopusid57759201300
dc.authorscopusid56592297600
dc.authorscopusid57242576700
dc.authorscopusid57759201400
dc.authorscopusid57226732046
dc.authorwosidKamaşak, Tülay/AAG-3642-2020
dc.contributor.authorKamasak, Tulay
dc.contributor.authorSerdaroglu, Esra
dc.contributor.authorYilmaz, Ozlem
dc.contributor.authorKilic, Betuel Aydin
dc.contributor.authorPolat, Burcin G.
dc.contributor.authorErdogan, Irmak
dc.contributor.authorSen, A. Derda Yucel
dc.date.accessioned2023-01-12T19:54:48Z
dc.date.available2023-01-12T19:54:48Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective: To evaluate the effectiveness and tolerability of clobazam therapy in the pediatric population in terms of seizure semiology, epileptic syndromes, and etiological subgroups.Methods: A retrospective cohort study was conducted consisting of 1710 epileptic children from eight centers in seven geographic regions of Turkey. The initial efficacy of clobazam therapy was evaluated after three months of treatment. The long-term effectiveness of the drug, overall seizure outcomes, and overall therapeutic outcomes were evaluated during 12 months of therapy. Results: Analysis of initial efficacy after the first three months of clobazam therapy showed that 320 (18.7 %) patients were seizure-free, 683 (39.9 %) had > 50 % seizure reductions, and 297 (17.4 %) had < 50 % seizure reductions. A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62.3 %) seizures, epileptic spasms (61.5 %), and generalized onset seisures (57.4). The highest positive response rate among the epileptic syndromes was for self-limited epilepsy with centrotemporal spikes (SeLECTS). The highest negative response rate was for developmental and/or epileptic encephalopathies (DEEs). Magnetic resonance imaging (MRI) revealed a structural etiological diagnosis in 25.8 % of the cohort. A higher positive response rate was observed at MRI in patients with sequelae lesions than in those with congenital lesions. The seizure recurrence rate was higher in the patient group with epilepsy with genetic and metabolic causes, in individuals with more than one seizure type, and in those using three or more antiseizure drugs.Conclusions: This cohort study provides additional evidence that clobazam is an effective and well-tolerable drug with a high seizure-free rate (18.7 %), a significant seizure reduction rate (57.3 %), and with excellent overall therapeutic outcomes with a low seizure relapse rate and considerable reversible benefits in the pediatric population.en_US
dc.identifier.doi10.1016/j.eplepsyres.2022.106963
dc.identifier.issn0920-1211
dc.identifier.issn1872-6844
dc.identifier.pmid35749975en_US
dc.identifier.scopus2-s2.0-85132518462en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.eplepsyres.2022.106963
dc.identifier.urihttps://hdl.handle.net/11454/76538
dc.identifier.volume184en_US
dc.identifier.wosWOS:000822813500002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEpilepsy Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectClobazamen_US
dc.subjectChildhood epilepsyen_US
dc.subjectWest syndromeen_US
dc.subjectLennox-Gastaut syndromeen_US
dc.subjectReversible effect of clobazamen_US
dc.subjectAdd-On Therapyen_US
dc.subjectRefractory Epilepsyen_US
dc.subjectAntiepileptic Drugen_US
dc.subjectChildhooden_US
dc.subjectEfficacyen_US
dc.subjectChildrenen_US
dc.subjectCarbamazepineen_US
dc.subjectExperienceen_US
dc.subjectPhenytoinen_US
dc.subjectSafetyen_US
dc.titleThe effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu